SequelSEC

NEOGENOMICS INC NEO

Services-Testing Laboratories · CIK 0001077183 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$201.66M
Fiscal year ended 2026-06-30
Operating income
-$9.77M
Fiscal year ended 2026-06-30
Free cash flow
$11.74M
Fiscal year ended 2026-06-30

NEOGENOMICS INC (NEO) reported revenue of $201.66M and net income of $2.24M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NEOGENOMICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Testing Laboratories.

Income

NEOGENOMICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$201.66M$186.67M$190.17M$187.80M$181.33M$168.04M$172.00M$167.82M$164.50M$156.24M
Cost of revenue$109.78M$105.81M$106.83M$107.35M$104.07M$94.79M$94.74M$92.94M$92.01M$90.77M
Gross profit$91.88M$80.86M$83.34M$80.45M$77.26M$73.25M$77.26M$74.88M$72.49M$65.47M
Operating income-$9.77M-$18.24M-$13.41M-$27.01M-$47.63M-$27.82M-$18.40M-$21.20M-$21.94M-$30.57M
Net income$2.24M-$17.11M-$9.88M-$27.13M-$45.09M-$25.92M-$15.32M-$17.70M-$18.64M-$27.06M
Research & development$10.76M$9.53M$9.18M$8.69M$9.02M$10.18M$7.97M$7.68M$7.89M$7.62M
Weighted-average diluted sharesshares 130.83Mshares 129.17MUnavailableshares 128.42Mshares 127.95Mshares 127.38MUnavailableshares 126.95Mshares 126.40Mshares 126.11M
Pretax income$1.83M-$17.58M-$12.41M-$26.39M-$45.82M-$25.66M-$16.13M-$17.85M-$19.02M-$27.68M
Income tax expense-$412.00K-$472.00K-$2.52M$740.00K-$724.00K$266.00K-$804.00K-$150.00K-$375.00K-$620.00K
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$90.89M$89.57M$86.95M$91.68M$95.82M$90.89M$85.98M$87.38M$85.00M$86.02M
General & administrative$63.61M$65.74M$63.51M$69.87M$71.75M$68.21M$63.64M$66.97M$63.33M$65.80M
Selling & marketing$27.28M$23.83M$23.44M$21.81M$24.08M$22.68M$22.34M$20.42M$21.68M$20.22M

Balance

NEOGENOMICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$145.54M$146.14M$159.62M$164.12M$154.72M$346.19M$367.01M$361.99M$355.08M$331.91M
Total assets$1.35B$1.35B$1.36B$1.37B$1.39B$1.60B$1.64B$1.64B$1.64B$1.64B
Current assets$381.48M$373.68M$376.29M$382.46M$392.55M$573.93M$596.02M$590.24M$584.20M$573.90M
Total liabilities$566.51M$517.77M$523.27M$536.49M$539.91M$713.16M$735.70M$732.90M$727.39M$716.93M
Current liabilities$105.88M$84.59M$88.30M$97.87M$100.12M$279.70M$301.24M$296.41M$289.96M$76.71M
Total equity incl. NCI$785.73M$828.76M$836.56M$838.29M$854.04M$888.27M$902.34M$908.21M$915.88M$923.41M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$27.14M$29.84M$28.57M$28.46M$34.17M$29.77M$26.75M$24.46M$23.21M$20.32M
Accounts receivable$175.40M$167.42M$159.24M$155.30M$153.12M$151.21M$150.54M$151.43M$146.58M$140.28M
Goodwill$524.00M$524.00M$524.34M$524.34M$524.14M$522.77M$522.77M$522.77M$522.77M$522.77M
Long-term debt$374.24MUnavailable$341.86MUnavailableUnavailableUnavailable$340.34MUnavailableUnavailableUnavailable
Accounts payable$20.95M$25.90M$23.09M$22.61M$27.49M$16.21M$21.61M$16.51M$17.19M$18.34M

Cash flow

NEOGENOMICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$19.96M-$8.14M$1.34M$8.88M$20.33M-$25.33M$9.80M$9.25M$13.89M-$25.92M
Capital expenditures$8.22M$5.00M$7.87M$8.31M$6.32M$4.50M$11.60M$10.80M$13.08M$5.58M
Investing cash flow-$8.32M-$5.00M-$6.30M-$277.00K-$9.31M$3.56M-$5.47M-$3.52M$7.31M$14.52M
Financing cash flow-$12.24M-$338.00K$431.00K$765.00K-$202.43M$949.00K$687.00K$1.18M$1.97M$816.00K
Net change in cashUnavailableUnavailableUnavailable$9.39MUnavailableUnavailableUnavailable$6.91M$23.17M-$10.57M
Stock-based compensation$8.22M$9.64M$8.04M$10.31M$12.21M$10.75M$8.33M$0$8.84M$7.77M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

NEOGENOMICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$11.74M-$13.14M-$6.53M$570.00K$14.01M-$29.83M-$1.80M-$1.55M$814.00K-$31.50M
Gross margin45.6%43.3%43.8%42.8%42.6%43.6%44.9%44.6%44.1%41.9%
Operating margin-4.8%-9.8%-7.1%-14.4%-26.3%-16.6%-10.7%-12.6%-13.3%-19.6%
FCF margin5.8%-7.0%-3.4%0.3%7.7%-17.8%-1.0%-0.9%0.5%-20.2%
SBC / revenue4.1%5.2%4.2%5.5%6.7%6.4%4.8%Unavailable5.4%5.0%
Current ratio3.60x4.42x4.26x3.91x3.92x2.05x1.98x1.99x2.01x7.48x
Revenue YoY growth11.2%11.1%10.6%11.9%10.2%7.5%10.6%10.4%12.0%13.9%
Net margin1.1%Unavailable-5.2%-14.4%-24.9%Unavailable-8.9%-10.5%UnavailableUnavailable
R&D / revenue5.3%5.1%4.8%4.6%5.0%6.1%4.6%4.6%4.8%4.9%
CapEx / revenue4.1%2.7%4.1%4.4%3.5%2.7%6.7%6.4%8.0%3.6%
Long-term debt / equity0.48xUnavailable0.41xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate-22.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NEO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-28View SEC filing
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-29View SEC filing
10-Q · Filed 2025-04-29View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.